Epigenetics of Cutaneous Melanoma

Advances in Dermatology

Volumn 24, Issue C, 2008, Pages 59-70

  Patino, Willmar D ^a   Susa, Joseph ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE;

ACETYLATION; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; HUMAN; MELANOMA; REVIEW; SKIN TUMOR; TUMOR SUPPRESSOR GENE;

ACETYLATION; DNA METHYLATION; EPIGENESIS, GENETIC; GENES, TUMOR SUPPRESSOR; HISTONES; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 56349090538     PISSN: 08820880     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yadr.2008.09.003     Document Type: Review

References (66)

1. Feinberg A.P. An epigenetic approach to cancer etiology. Cancer J 13 1 (2007) 70-74
2. Van Doorn R., Gruis N.A., Willemze R., et al. Aberrant DNA methylation in cutaneous malignancies. Semin Oncol 32 5 (2005) 479-487
3. Rothhammer T., and Bosserhoff A.K. Epigenetic events in malignant melanoma. Pigment Cell Res 20 2 (2007) 92-111
4. Svensson Mansson S., Reis-Filho J., and Landberg G. Transcriptional upregulation and unmethylation of the promoter region of p16 in invasive basal cell carcinoma cells and partial co-localization with the gamma 2 chain of laminin-332. J Pathol 212 1 (2007) 102-111
5. Goelz S.E., Vogelstein B., Hamilton S.R., et al. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 228 (1985) 187-190
6. Jones P.A., and Baylin S.B. The epigenomics of cancer. Cell 128 4 (2007) 683-692
7. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8 4 (2007) 286-298
8. Costello J.F., Fruhwald M.C., Smiraglia D.J., et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24 (2000) 132-138
9. Esteller M., Corn P.G., Baylin S.B., et al. A gene hypermethylation profile of human cancer. Cancer Res 61 (2001) 3225-3229
10. Brueckner B., Kuck D., and Lyko F. DNA methyltransferase inhibitors for cancer therapy. Cancer J 13 1 (2007) 17-22 [cells. Sb Lek 97:29-39, 1996]
11. Worm J., Christensen C., Gronbaek K., et al. Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene 23 (2004) 5215-5226
12. Worm J., Bartkova J., Kirkin A.F., et al. Aberrant p27Kip1 promoter methylation in malignant melanoma. Oncogene 19 44 (2000) 5111-5115
13. Gonzalgo M.L., Bender C.M., You E.H., et al. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res 57 (1997) 5336-5347
14. Straume O., Smeds J., Kumar R., et al. Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol 161 (2002) 229-237
15. Marini A., Mirmohammadsadegh A., Nambiar S., et al. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. J Invest Dermatol 126 2 (2006) 422-431
16. Hoon D.S., Spugnardi M., Kuo C., et al. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23 22 (2004) 4014-4022
17. Furuta J., Nobeyama Y., Umebayashi Y., et al. Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. Cancer Res 66 12 (2006) 6080-6086
18. Spugnardi M., Tommasi S., Dammann R., et al. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 63 (2003) 1639-1643
19. Furuta J., Umebayashi Y., Miyamoto K., et al. Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci 95 (2004) 962-968
20. Tokita T., Maesawa C., Kimura T., et al. Methylation status of the SOCS3 gene in human malignant melanomas. Int J Oncol 30 3 (2007) 689-694
21. Furuta J., Kaneda A., Umebayashi Y., et al. Silencing of the thrombomodulin gene in human malignant melanoma. Melanoma Res 15 (2005) 15-20
22. Guan X., Sagara J., Yokoyama T., et al. ASC/TMS1, a caspase-1 activating adaptor, is downregulated by aberrant methylation in human melanoma. Int J Cancer 107 (2003) 202-208
23. In: LeBoit P.E., Burg G., Weedon D., et al. (Eds). Pathology and genetics of head and neck tumors: IARC WHO classification of tumors. World Health Organization (2005), IARC Press, Lyon, France
24. Miller A.J., and Mihm Jr. M.C. Melanoma. N Engl J Med 355 1 (2006) 51-65
25. Mittal A., Piyathilake C., Hara Y., et al. Exceptionally high protection of photocarcinogenesis by topical application of (-)-epigallocatechin-3-gallate in hydrophilic cream in SKH-1 hairless mouse model: relationship to inhibition of UVB-induced global DNA hypomethylation. Neoplasia 5 (2003) 555-565
26. Rocco J.W., and Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 264 1 (2001) 42-55
27. De Smet C., De Backer O., Faraoni I., et al. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A 93 14 (1996) 7149-7153
28. Sigalotti L., Coral S., Nardi G., et al. Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma. J Immunother 25 1 (2002) 16-26
29. Coral S., Sigalotti L., Colizzi F., et al. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. J Cell Physiol 207 1 (2006) 58-66
30. Van Grunsven L.A., Verstappen G., Huylebroeck D., et al. Smads and chromatin modulation. Cytokine Growth Factor Rev 16 (2005) 495-512
31. Carrozza M.J., Utley R.T., Workman J.L., et al. The diverse functions of histone acetyltransferase complexes. Trends Genet 19 (2003) 321-329
32. Adhikary S., and Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6 (2005) 635-645
33. Bandyopadhyay D., Okan N.A., Bales E., et al. Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Cancer Res 62 (2002) 6231-6239
34. Tulley P.N., Neale M., Jackson D., et al. The relation between c-myc expression and interferon sensitivity in uveal melanoma. Br J Ophthalmol 88 (2004) 1563-1567
35. Nomura T., Tanikawa J., Akimaru H., et al. Oncogenic activation of c-Myb correlates with a loss of negative regulation by TIF1beta and Ski. J Biol Chem 279 16 (2004) 715-726
36. Reed J.A., Lin Q., Chen D., et al. SKI pathways inducing progression of human melanoma. Cancer Metastasis Rev 24 (2005) 265-272
37. Shi Y., Lan F., Matson C., et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119 (2004) 941-953
38. Dong Z., and Bode A.M. The role of histone H3 phosphorylation (Ser10 and Ser28) in cell growth and cell transformation. Mol Carcinog 45 (2006) 416-421
39. Dunn K.L., Espino P.S., Drobic B., et al. The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem Cell Biol 83 (2005) 1-14
40. Nowak S.J., and Corces V.G. Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation. Trends Genet 20 (2004) 214-220
41. Santos-Rosa H., and Caldas C. Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 41 (2005) 2381-2402
42. Bergink S., Salomons F.A., Hoogstraten D., et al. DNA damage triggers nucleotide excision repair-dependent monoubiquitylation of histone H2A. Genes Dev 20 (2006) 1343-1352
43. Abele R., Clavel M., Dodion P., et al. The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol 23 12 (1987) 1921-1924
44. Gollob J.A., Sciambi C.J., Peterson B.L., et al. Phase I trial of sequential low-dose 5-aza-2′-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 12 15 (2006) 4619-4627
45. Soengas M.S., Capodieci P., Polsky D., et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409 6817 (2001) 141-144
46. Glaser K.B., Staver M.J., Waring J.F., et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2 (2003) 151-163
47. Scwabe M., and Lubbert M. Epigenetic lesions in malignant melanoma. Curr Pharm Biotechnol 8 (2007) 382-387
48. Boyle G.M., Martyn A.C., and Parsons P.G. Pigment Cell Res 18 3 (2005) 160-166
49. Saito A., Yamashita T., Mariko Y., et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A 96 (1999) 4592-4597
50. Facchetti F., Previdi S., Ballarini M., et al. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 9 (2004) 573-582
51. Peltonen K., Kiviharju T.M., Jarvinen P.M., et al. Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis. Pigment Cell Res 18 (2005) 196-202
52. Kobayashi Y., Ohtsuki M., Murakami T., et al. Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma. Oncogene 25 (2006) 512-524
53. Medina V., Edmonds B., Young G.P., et al. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 57 (1997) 3697-3707
54. Bandyopadhyay D., Mishra A., and Medrano E.E. Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res 64 21 (2004) 7706-7710
55. Chou S.-D., Khan A.N.H., Magner W.J., et al. Histone acetylation regulates the cell type speciWc CIITA promoter, MHC class II expression and antigen presentation in tumor cells. Int Immunol 17 (2005) 1483-1494
56. Kahn A.N.H., Gregorie C.J., and Tomasi T.B. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother 57 (2008) 647-654
57. Munshi A., Kurland J.F., Nishikawa T., et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 11 13 (2005) 4912-4922
58. Johanning G.L., Heimburger D.C., and Piyathilake C.J. DNA methylation and diet in cancer. J Nutr 132 (2002) 3814S-3818S
59. Weidman J.R., Dolinoy D.C., Murphy S.K., et al. Cancer susceptibility: epigenetic manifestation of environmental exposures. Cancer J 13 1 (2007) 9-16
60. Pfeifer G.P. p53 mutational spectra and the role of methylated CpG sequences. Mutat Res 450 (2000) 155-166
61. Tommasi S., Denissenko M.F., and Pfeifer G.P. Sunlight induces pyrimidine dimers preferentially at 5-methylcytosine bases. Cancer Res 57 (1997) 4727-4730
62. Sharonov A., Gustavsson T., Marguet S., et al. Photophysical properties of 5-methylcytidine. Photochem Photobiol Sci 2 (2003) 362-364
63. Denissenko M.F., Chen J.X., Tang M.S., et al. Cytosine methylation determines hot spots of DNA damage in the human P53 gene. Proc Natl Acad Sci U S A 94 (1997) 3893-3898
64. You Y.H., and Pfeifer G.P. Similarities in sunlight-induced mutational spectra of CpG-methylated transgenes and the p53 gene in skin cancer point to an important role of 5-methylcytosine residues in solar UV mutagenesis. J Mol Biol 305 (2001) 389-399
65. Sathyanarayana U.G., Moore A.Y., Li L., et al. Sun exposure related methylation in malignant and non-malignant skin lesions. Cancer Lett 245 1-2 (2007) 112-122
66. Tsutsumida A., Hamada J., Tada M., et al. Epigenetic silencing of E- and P-cadherin gene expression in human melanoma cell lines. Int J Oncol 25 5 (2004) 1415-1421